What is HC Wainwright’s Forecast for ACRV Q1 Earnings?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Acrivon Therapeutics in a research report issued to clients and investors on Wednesday, March 26th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.63) for the quarter. HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.77) EPS, FY2027 earnings at ($2.31) EPS and FY2028 earnings at ($1.96) EPS.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.06.

Several other research analysts also recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Acrivon Therapeutics in a report on Wednesday. KeyCorp assumed coverage on Acrivon Therapeutics in a report on Friday, January 31st. They issued an “overweight” rating on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Acrivon Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $23.17.

Acrivon Therapeutics Stock Down 3.4 %

Shares of Acrivon Therapeutics stock opened at $2.52 on Friday. The stock has a market cap of $78.46 million, a price-to-earnings ratio of -0.93 and a beta of 0.85. Acrivon Therapeutics has a twelve month low of $2.44 and a twelve month high of $11.90. The company’s fifty day moving average is $5.42 and its 200 day moving average is $6.57.

Institutional Trading of Acrivon Therapeutics

Several hedge funds have recently modified their holdings of ACRV. Acorn Capital Advisors LLC acquired a new position in shares of Acrivon Therapeutics during the fourth quarter valued at about $2,440,000. Exome Asset Management LLC acquired a new position in Acrivon Therapeutics during the 3rd quarter worth approximately $817,000. State Street Corp lifted its holdings in shares of Acrivon Therapeutics by 26.4% in the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after purchasing an additional 47,233 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Acrivon Therapeutics by 548.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after purchasing an additional 28,748 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Acrivon Therapeutics by 29.7% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company’s stock worth $619,000 after buying an additional 23,535 shares during the last quarter. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.